BACKGROUND: Everolimus, a mammalian target of rapamycin (mTOR) inhibitor, has been shown to be effective and safe in the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC). The Everolimus For Fast Expanded aCcess in TSC SEGA (EFFECTS) study was designed to provide everolimus access to patients with SEGA associated with TSC and to mainly assess the safety and also efficacy of everolimus in a real-world setting. METHODS: EFFECTS was a phase 3b, open-label, noncomparative, multicenter, expanded access study. Eligible patients were ≥ 3 years of age, with a definite diagnosis of TSC, and with at least one SEGA lesion identified by MRI or CT scan. Patients received once daily everolimus (dose adjusted to attain a trough level of 5-15 ng/mL). Safety evaluation was the primary objective and included collection of adverse events (AEs) and serious AEs, with their severity and relationship to everolimus. Efficacy evaluation, which was the secondary objective, was based on the best overall response as per medical judgment. RESULTS: Of the 120 patients enrolled, 100 (83.3%) completed the study. Median age of patients was 11 years (range, 1-47). Median daily dose of everolimus was 5.82 mg (range, 2.0-11.8). Median duration of exposure was 56.5 weeks (range, 0.3-130). The overall incidence of AEs was 74.2%. Aphthous stomatitis (18 [15.0%]), pyrexia (18 [15.0%]), bronchitis (11 [9.2%]), and stomatitis (10 [8.3%]) were the most common AEs reported. Overall, 25 patients had grade 3 AEs; most frequent was stomatitis (4 [3.3%]). Grade 4 AEs were reported in three (2.5%) patients. A total of 62 (51.7%) patients had suspected drug-related AEs, of which 15 (12.5%) were of grade 3 or 4. In eight (6.7%) patients, AEs led to drug discontinuation. With regard to efficacy, 81 (67.5%) patients had a partial response, 35 (29.2%) had a stable disease, and one (0.8%) had progressive disease. The response was unknown in three (2.5%) patients. CONCLUSION: This study confirms the acceptable safety profile of everolimus in patients with SEGA associated with TSC in a real-world setting. The results further support the efficacy of everolimus in the treatment of SEGA associated with TSC. (EudraCT: 2010-022583-13).

Children's Memorial Health Institute Warsaw Poland

CHU Pellegrin Hôpital des Enfants Bordeaux France

Department of Pediatric Neurology Medical University of Warsaw Warsaw Poland

Gasthuisberg University Hospitals Leuven Leuven Belgium

German Cancer Research Center and Section of Pediatric Brain Tumors University Hospital Heidelberg Germany

Ghent University Hospital Ghent Belgium

Motol University Hospital Prague Czech Republic

National Institute of Neurosciences Budapest Hungary

Neonatology and NICU Section DIMO University of Bari Bari Italy

Neurology Department Bethesda Children's Hospital Bethesda Street 3 H 1146 Budapest Hungary

Novartis Farma S p A Origgio Italy

Novartis Farmacéutica SA Barcelona Spain

Pediatric Unit University Hospital Siena Italy

See more in PubMed

Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med. 2006;355(13):1345–56. doi: 10.1056/NEJMra055323. PubMed DOI

Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet. 2008;372(9639):657–68. doi: 10.1016/S0140-6736(08)61279-9. PubMed DOI

Curatolo P, Maria BL. Tuberous sclerosis. Handb Clin Neurol. 2013;111:323–31. doi: 10.1016/B978-0-444-52891-9.00038-5. PubMed DOI

Northrup H, Krueger DA, International Tuberous Sclerosis Complex Consensus G Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2013;49(4):243–54. doi: 10.1016/j.pediatrneurol.2013.08.001. PubMed DOI PMC

Franz DN, Bissler JJ, McCormack FX. Tuberous sclerosis complex: neurological, renal and pulmonary manifestations. Neuropediatrics. 2010;41(5):199–208. doi: 10.1055/s-0030-1269906. PubMed DOI PMC

Goh S, Butler W, Thiele EA. Subependymal giant cell tumors in tuberous sclerosis complex. Neurology. 2004;63(8):1457–61. doi: 10.1212/01.WNL.0000142039.14522.1A. PubMed DOI

Roszkowski M, Drabik K, Barszcz S, Jozwiak S. Surgical treatment of intraventricular tumors associated with tuberous sclerosis. Childs Nerv Syst. 1995;11(6):335–9. doi: 10.1007/BF00301665. PubMed DOI

Kotulska K, Borkowska J, Roszkowski M, Mandera M, Daszkiewicz P, Drabik K, Jurkiewicz E, Larysz-Brysz M, Nowak K, Grajkowska W, et al. Surgical treatment of subependymal giant cell astrocytoma in tuberous sclerosis complex patients. Pediatr Neurol. 2014;50(4):307–12. doi: 10.1016/j.pediatrneurol.2013.12.004. PubMed DOI

Franz DN, Leonard J, Tudor C, Chuck G, Care M, Sethuraman G, Dinopoulos A, Thomas G, Crone KR. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol. 2006;59(3):490–8. doi: 10.1002/ana.20784. PubMed DOI

Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T, Franz DN. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010;363(19):1801–11. doi: 10.1056/NEJMoa1001671. PubMed DOI

Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2013;381(9861):125–32. doi: 10.1016/S0140-6736(12)61134-9. PubMed DOI

Votubia (Everolimus) Summary of Product Characteristics. West Sussex, UK: Novartis Europharm Limited; 2014. [http://www.votubia.com/pdf/Votubia-SMPC%20for%20website%2002-2015-V1.pdf]. Accessed 18 June 2015.

Afinitor (Everolimus) Tablets for Oral Administration Prescribing Information. New Jersey, NJ: Novartis Pharmaceuticals Corporation; 2014. [https://www.pharma.us.novartis.com/product/pi/pdf/afinitor.pdf]. Accessed 18 June 2015.

Roach ES, Gomez MR, Northrup H. Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria. J Child Neurol. 1998;13(12):624–8. doi: 10.1177/088307389801301206. PubMed DOI

World Medical A World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. Jama. 2013;310(20):2191–4. doi: 10.1001/jama.2013.281053. PubMed DOI

National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. National Institutes of Health, US Department of Health and Human Services; 2009. [http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf]. Accessed 18 June 2015.

Jozwiak S, Nabbout R, Participants of the TSCCMfS. Curatolo P, Epilepsy M. Management of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): Clinical recommendations. Eur J Paediatr Neurol. 2013;17(4):348–52. doi: 10.1016/j.ejpn.2012.12.008. PubMed DOI

Krueger DA, Northrup H, International Tuberous Sclerosis Complex Consensus G Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2013;49(4):255–65. doi: 10.1016/j.pediatrneurol.2013.08.002. PubMed DOI PMC

Roth J, Roach ES, Bartels U, Jozwiak S, Koenig MK, Weiner HL, Franz DN, Wang HZ. Subependymal giant cell astrocytoma: diagnosis, screening, and treatment. Recommendations from the International Tuberous Sclerosis Complex Consensus Conference 2012. Pediatr Neurol. 2013;49(6):439–44. doi: 10.1016/j.pediatrneurol.2013.08.017. PubMed DOI

Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, Sauter M, Nonomura N, Brakemeier S, de Vries PJ, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2013;381(9869):817–24. doi: 10.1016/S0140-6736(12)61767-X. PubMed DOI

Cappellano AM, Senerchia AA, Adolfo F, Paiva PM, Pinho R, Covic A, Cavalheiro S, Saba N. Successful everolimus therapy for SEGA in pediatric patients with tuberous sclerosis complex. Childs Nerv Syst. 2013;29(12):2301–5. doi: 10.1007/s00381-013-2170-0. PubMed DOI

Curatolo P, Moavero R. mTOR Inhibitors in Tuberous Sclerosis Complex. Curr Neuropharmacol. 2012;10(4):404–15. doi: 10.2174/1570159X11209040404. PubMed DOI PMC

Davies DM, de Vries PJ, Johnson SR, McCartney DL, Cox JA, Serra AL, Watson PC, Howe CJ, Doyle T, Pointon K, et al. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin. Cancer Res. 2011;17(12):4071–81. doi: 10.1158/1078-0432.CCR-11-0445. PubMed DOI

Kohrman MH. Emerging treatments in the management of tuberous sclerosis complex. Pediatr Neurol. 2012;46(5):267–75. doi: 10.1016/j.pediatrneurol.2012.02.015. PubMed DOI

Kotulska K, Chmielewski D, Borkowska J, Jurkiewicz E, Kuczynski D, Kmiec T, Lojszczyk B, Dunin-Wasowicz D, Jozwiak S. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. Eur J Paediatr Neurol. 2013;17(5):479–85. doi: 10.1016/j.ejpn.2013.03.002. PubMed DOI

Krueger DA, Wilfong AA, Holland-Bouley K, Anderson AE, Agricola K, Tudor C, Mays M, Lopez CM, Kim MO, Franz DN. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann Neurol. 2013;74(5):679–87. doi: 10.1002/ana.23960. PubMed DOI

McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011;364(17):1595–606. doi: 10.1056/NEJMoa1100391. PubMed DOI PMC

Amin S, Carter M, Edwards RJ, Pople I, Aquilina K, Merrifield J, Osborne JP, O'Callaghan FJ. The outcome of surgical management of subependymal giant cell astrocytoma in tuberous sclerosis complex. Eur J Paediatr Neurol. 2013;17(1):36–44. doi: 10.1016/j.ejpn.2012.10.005. PubMed DOI

Harter DH, Bassani L, Rodgers SD, Roth J, Devinsky O, Carlson C, Wisoff JH, Weiner HL. A management strategy for intraventricular subependymal giant cell astrocytomas in tuberous sclerosis complex. J Neurosurg Pediatr. 2014;13(1):21–8. doi: 10.3171/2013.9.PEDS13193. PubMed DOI

Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, et al. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. Lancet Oncol. 2014;15(13):1513–20. doi: 10.1016/S1470-2045(14)70489-9. PubMed DOI

Krueger DA, Care MM, Agricola K, Tudor C, Mays M, Franz DN. Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma. Neurology. 2013;80(6):574–80. doi: 10.1212/WNL.0b013e3182815428. PubMed DOI PMC

Roa J, Tena-Sempere M. Energy balance and puberty onset: emerging role of central mTOR signaling. Trends Endocrinol Metabol: TEM. 2010;21(9):519–28. doi: 10.1016/j.tem.2010.05.003. PubMed DOI

Northrup H. The mTOR inhibitor revolution rolls on. Lancet Oncol. 2014;15(13):1418. doi: 10.1016/S1470-2045(14)71101-5. PubMed DOI

See more in PubMed

EudraCT
2010-022583-13